1. Home
  2. VHC vs ACET Comparison

VHC vs ACET Comparison

Compare VHC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

HOLD

Current Price

$14.63

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.01

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHC
ACET
Founded
2005
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
69.6M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
VHC
ACET
Price
$14.63
$7.01
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
10.0K
174.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
35.17
59.82
EPS
N/A
N/A
Revenue
$5,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$0.45
52 Week High
$29.00
$9.05

Technical Indicators

Market Signals
Indicator
VHC
ACET
Relative Strength Index (RSI) 35.83 48.89
Support Level $12.53 $0.62
Resistance Level $21.31 $8.46
Average True Range (ATR) 1.64 0.53
MACD -0.26 -0.08
Stochastic Oscillator 14.66 50.43

Price Performance

Historical Comparison
VHC
ACET

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: